BIA response to the International Trade Committee's inquiry on UK trade with China

The BIA has responded to the House of Commons International Trade Committee's inquiry into the UK's trade with China. 

In our submission, we highlighted:

• With its large healthcare and pharmaceutical market and emerging excellence in science, China offers many opportunities for UK life sciences companies. These opportunities encompass big data, new healthcare systems, digital, diagnostics, genomics and new medicines, which will all be at the heart of the new healthcare landscape that is emerging in China.
• In the last two years China has made a concerted attempt to, and has delivered, fundamental changes to key aspects of its healthcare market, including new approaches to medicines regulation, reimbursement of drugs, talent, and capital and public markets. Ties between UK-Chinese institutions, especially regulators, must be strengthened to maintain UK influence in global affairs.
• The BIA is committed to building strong links between the UK and Chinese innovation systems. In 2018, we established a China Biotech Special Interest Group together with the China-Britain Business Council. In the past two years, we have attended and led delegations of UK SMEs to several major conferences in China.